safety of glp-1 receptor agonists Exploring the Side Effects Agonist: To Ensure Its Optimal Positioning Frontiers | Exploring the multifaceted

A 24-week multicenter, randomized, double-blind, placebo-controlled clinical study conducted by Apovian (53) found that EX combined with lifestyle adjustment could significantly reduce the weight of patients, all of which were 6.16 0.54 kg

Bullock BP, Heller RS, and Habener JF

The growth in the forecast period can be attributed to growing obesity population, expanding approval for cardiovascular risk reduction, innovation in oral and combination therapies, increased penetration in emerging markets, rising patient preference for weight loss benefits

Moreover, small-molecule GLP-1RAs offer a solution to the bioavailability limitations faced by oral peptide-based agents, which often depend on absorption enhancers (e.g., SNAC) and strict fasting protocols [74]

doi: 10.3390/ijms242316735

GLP-1 receptor agonists should be used with caution in patients with gastroparesis or severe gastroesophageal reflux disease, with careful monitoring and dose adjustments as needed (36)